NEW YORK--(BUSINESS WIRE)--Cowen Group, Inc. (“Cowen”) (NASDAQ: COWN) today announced that Edward Nash has joined the firm as Director and Senior Research Analyst. Based in New York, Mr. Nash will cover biotechnology in the health care sector of Cowen’s Research group and report to Barry Tarasoff, Cowen’s Director of Research.
"It is with pleasure that we welcome Edward to Cowen,” commented Barry Tarasoff. “His addition further enhances Cowen’s growing biotechnology team and augments our leading healthcare coverage. We look forward to the valuable contributions he will make to the firm.”
Mr. Nash joins Cowen from ROTH Capital Partners where he was a Senior Analyst covering biotechnology. While at ROTH, Mr. Nash focused on the therapeutic areas of HCV, RNAi, vaccines, and drug delivery. Prior to this, Mr. Nash was a Senior Analyst at Merriman Curhan Ford, Inc. and held similar roles at Stifel, Nicolaus & Company, Rodman & Renshaw, Inc., and SG Cowen Asset Management, Inc.
Mr. Nash received his B.S. from Spring Hill College in Biology and Chemistry and an M.P.H. in Epidemiology from University of Alabama at Birmingham. He also holds an MBA in Finance and an M.S. in International Business from University of Miami.
About Cowen Group, Inc.
Cowen Group, Inc. is a leading diversified financial services firm providing alternative investment management, investment banking, research, and sales and trading services through its business units, Ramius and Cowen and Company. Its alternative investment management products include hedge funds, fund of funds, real estate funds, healthcare royalty funds, cash management and commodity trading funds, offered primarily under the Ramius name. Cowen and Company offers industry focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Founded in 1918, the firm is headquartered in New York and has offices located in major financial centers around the world.